KR20190037879A - Composition comprising Hibiscus syriacus L. extract for inhibiting antimicrobial peptides - Google Patents

Abstract

Disclosed in the present specification is a composition comprising a Hibiscus syriacus extract as an active ingredient. The composition for inhibiting antibacterial peptides regulates the expression level of S100A7 (NM_002963), an antibacterial peptide, to a normal level. By using the composition for inhibiting antibacterial peptides, the increased expression level of the antibacterial peptides due to various causes can return to a normal level.

Description

Composition comprising Hibiscus syriacus L. extract for inhibiting antimicrobial peptides,

Disclosed herein are compositions that inhibit antimicrobial peptides. More particularly, the present invention discloses a composition comprising an extract of Mugunghwa, which significantly changes the expression level of an antimicrobial peptide whose expression level is changed compared to normal skin cells by various causes.

Antimicrobial peptides are similar in function to antibiotics and have been shown to be effective in enhancing immune responses.

Antimicrobial peptides are a type of immunosuppressive system that nonspecifically binds to microbial invasion from the outside of microorganisms, plants, insects, amphibians, and mammals. Structurally, it contains a large number of amino acids with positive charge in the sequence and exhibits a wide range of antibacterial activity ranging from Gram positive group, Gram negative bacteria, fungi, and cancer cells.

When these peptides bind to the cell membrane, they form an ion channel in the cell membrane, which inhibits the energy production of the microorganism, or makes a large hole in the cell membrane, and eventually kills the cell. In this short period of time, there is a characteristic that it has a mechanism of destroying the cell membrane by a non-specific and effective physical method.

However, excessive antimicrobial peptides can have rather detrimental effects. For example, it is well known that S100A7, a member of the S100 protein family, is an antimicrobial peptide. Although the exact mechanism is not known, the fact that the epidermal differentiation is damaged during the treatment of the recombinant S100A7 peptide and that the antimicrobial protein S100A7 is present in excess as in skin cells with atopic dermatitis (AD) and psoriasis lesions (Negative regulator) in epidermal differentiation (see Non-Patent Document 1).

Therefore, there is a need to inhibit antimicrobial peptides in skin cells as a means for treating skin cell damage.

Son et al., "S100A7 (psoriasis) inhibits human epidermal differentiation by enhanced IL-6 secretion through IκB / NF-κB signaling ", Experimental Dermatology. 2016 Aug; 25 (8): 636-41. Kim, H.J., et al., "Transcriptome analysis of airborne PM2.5-induced detrimental effects on human keratinocytes ", Toxicology Letters 273, 26-35,

In one aspect, the present invention provides a composition for inhibiting antimicrobial peptides.

In order to accomplish the above object, in one aspect, the present invention provides a composition for inhibiting antimicrobial peptides that regulates the expression level of S100A7 (NM_002963), which is an antibacterial peptide, to a normal level, .

In one aspect, by using the composition for inhibiting antimicrobial peptides provided by the present invention, the expression level of the antimicrobial peptide increased by various causes can be returned to a normal level.

1 shows the cell survival rate by treatment with a fine dust extract, wherein ADSP represents Asian dust-storm particles, and PM10 (Particulate matter 10) represents fine dust particles having a particle size of 10 μm And PM2.5 (Particulate matter 2.5) represents fine dust having a particle size of 2.5 mu m.
FIG. 2 shows an increase in mRNA expression of S100A7 gene in skin cells stimulated by PM2.5 microparticles, and a return to a normal level by treatment with hibiscus extract.

Hereinafter, the present invention will be described in detail.

In one aspect of the present invention, the composition for inhibiting antimicrobial peptides may include an extract of hibiscus as an active ingredient.

Hibiscus syriacus L. belongs to the deciduous shrub of the dicotyledonous plant, The height is 3-4 meters, and the young branches have many hairs but gradually disappear. Mugunghwa is easy to cultivate in the garden and it can reproduce with seeds, but it is easy to keep the traits without deforming because it grows with the knife. Leaves are alternate phyllotaxis, usually divided into three, with sawtooth on edge. The husk of Mugunghwa is stripped and used as a raw material for paper, dried and used as a medicine. Young leaves are edible, flowers and leaves can be drunk.

Mugunghwa is an antioxidant and its main component is saponarin which has germane effect. It is known that roots and bark of Hibiscus roots contain tannic acid, flowers and leaves contain saponin, and malvalic acid and sterolic acid.

Dongbok-bop and basal gangmok are used for athlete's foot and hemorrhoid pain, roots and shells are moon or worry, and they are used for athlete's foot and hemorrhoid pain. When you take flowers and leaves together with hot water after taking them with hot water, they are effective to relieve thirst, thirst, vomiting and appetite. , And the slave and the fox are fuming the affected part with the smoke burning it, and it can be used as a headache, migraine treatment, and antibiotic treatment. Other efficacies include stopping the blood (泻 血), inducing the fever, detoxification, extinction, gynecological diseases, vomiting, pain and swelling, preventing hair loss and hair loss, bronchitis, inflammation, enteritis, Insecticidal effects and the like.

In the past, Mugunghwa was used as a horticultural crop in Korea. The rosemary petals make rice cakes and tea. Young rosemary leaves are used to make herbs and miso soup. In Europe and China, leaves and flowers are used as herbal tea and buds cooked as spices for court cuisine are used. In addition, fibers are obtained from the bark of Mugunghwa and used as papermaking materials.

In one aspect, the composition of the present invention can utilize leaves, stems, husks, roots, fruits, flowers or buds of hibiscus, seeds and the like. Specifically, the composition of the present invention may be used as an extract of leaves, stems, husks, roots, fruits, flowers or buds, and seeds of hibiscus. In one embodiment, the composition of the present invention may be selected from the group consisting of Hibiscus bark extract Hibiscus syriacus BARK EXTRACT).

In one aspect of the invention, the hibiscus can be extracted with a particular extraction solvent to form a hibiscus extract.

In one aspect of the present invention, the above-mentioned hibiscus extract may be prepared by extracting Hibiscus with water or an organic solvent. Specifically, it is preferable that the hibiscus is extracted with at least one selected from the group consisting of water, C ₁ -C ₆ anhydrous or lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane Followed by extraction with a solvent.

In one aspect, the above-mentioned hibiscus extract may be extracted at room temperature.

In one aspect, the hibiscus extract may be one obtained by further extracting one or more of evaporation, filtration, concentration, separation or drying after extraction with the extraction solvent. In particular, the above-mentioned hibiscus extract may be subjected to one or more filtration processes, and in one embodiment, it is subjected to two filtration processes.

In one embodiment, the separation process may include a centrifugation process.

Specifically, the extraction can be carried out in the presence of water, a C ₁ -C ₆ anhydrous or a lower alcohol, a polar solvent comprising acetone and butylene glycol, and a polar solvent including ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane And a low polarity solvent may be used as a solvent.

More specifically, the solvent may be 50-90% ethanol aqueous solution, and may be 60-80% ethanol or 65-75% ethanol aqueous solution. When the solvent is an aqueous 50 to 90% ethanol solution, the active ingredient can be effectively extracted from the hibiscus. In one embodiment, the solvent may be about 70% aqueous ethanol solution.

In one aspect, the extract may be concentrated under reduced pressure to an appropriate temperature in a distillation apparatus equipped with a cooling condenser after extraction.

However, the extract of Mugungwha according to the present invention can be extracted by a conventional method in the art, and is not limited by the above-mentioned method.

In one aspect of the present invention, the composition may comprise from 0.000001 to 30% by weight of the hibiscus oil extract, based on the total weight of the composition. When the content thereof is 0.000001 to 30% by weight, the skin care effect by fine dust caused by the hibiscus extract is excellent.

More specifically, 0.0000001 wt% or more, 0.0000005 wt% or more, 0.0000007 wt% or more, 0.0000009 wt% or more, 0.0000009 wt% or more, 0.000001 wt% or more, 0.000002 wt% or more, 0.000004 wt% or more, 0.000006 wt% or more, 0.000008 wt. At least 0.00003% by weight, at least 0.00005% by weight, at least 0.00007% by weight, at least 0.00009% by weight, at least 0.00009% by weight, at least 0.0001% by weight, at least 0.0003% by weight, at least 0.0005% by weight, at least 0.0007% by weight, % Or more, 0.01 wt% or more, 0.1 wt% or more, 1 wt% or more, 3 wt% or more, 5 wt% or more, 7 wt% or more, 9 wt% or more, 10 wt% or more, 13 wt% or more, Or more, 17 wt% or more, 19 wt% or more, 21 wt% or more, 23 wt% or more, 25 wt% or more, 27 wt% or more, 29 wt% or more, 30 wt% or more, 31 wt% 32 weight% or less, 31 weight% or less, 30 weight% or less, 29 weight% or less, 28 weight% or less, 26 weight% or less, 24 weight % Or less, 22 wt% or less, 20 wt% or less, 18 wt% or less, 16 wt% or less, 14 wt% or less, 12 wt% or less, 10 wt% or less, 9 wt% or less, 8 wt% % Or less, 4 wt% or less, 2 wt% or less, 1 wt% or less, 0.1 wt% or less, 0.09 wt% or less, 0.04 wt% or less, 0.01 wt% or less, 0.006 wt% or less, 0.001 wt% 0.000003 wt.% Or less, 0.00003 wt.% Or less, 0.00001 wt.% Or less, 0.00001 wt.% Or less, 0.000009 wt.% Or less, 0.000007 wt.% Or less, 0.000005 wt. %, 0.0000007 wt% or less, 0.0000005 wt% or less, 0.0000003 wt% or less, 0.0000002 wt% or less, 0.0000001 wt% or less, or 0.00000009 wt% or less.

Another aspect of the invention includes the use of the composition for inhibiting antimicrobial peptides.

As used herein, the term "fine dust" refers to a particulate matter that is a very small material that is invisible to the naked eye and that floats or drifts in the air for a long time. Particularly, particulate matter having a particle size of 2.5 μm or less is called "ultrafine dust". In the present invention, "fine dust" is also intended to include "ultrafine dust".

In one aspect, the present invention provides a composition for inhibiting an antimicrobial peptide by controlling the expression level of a specific gene in a skin cell to a normal level.

Specifically, in the present invention, the expression amount of S100A7 (NM_002963), which is an antimicrobial peptide, may be affected by various causes. When the expression amount of the antibacterial peptide S100A7 (NM_002963) is increased due to such a cause, By inhibiting the expression levels of these genes and regulating them to normal levels, antimicrobial peptides can be inhibited.

The genes whose expression levels are increased by various causes, which are used in the present invention, are shown in [Table 1]. [Table 1] shows genes that are antimicrobial peptides with increased expression levels. In these tables, Name means the genebank accession ID of NCBI, Gene Symbol means the official gene symbol, and Gene title means the name of each gene it means. This content can be confirmed through the description of Non-Patent Document 2.

Increase gene Name Gene
Symbol Gene title NM_002963 S100A7 S100 calcium binding protein A7

Analysis of the expression level of the gene or protein can be performed using a microarray, PCR, NGS (Nest Generation Sequencing), Western blot, northern blot, ELISA, radioimmunoassay, radioimmunoassay, tissue immuno staining, Can be analyzed using a variety of analytical methods known in the art.

In one aspect of the present invention, the composition may be a cosmetic composition, a pharmaceutical composition, or a health functional food composition.

Examples of the cosmetic composition include cosmetics such as various creams, lotion creams, lotions, skins, and the like, and cleansing, cleansing agents, soaps, and essences.

In one aspect, the cosmetic composition to which the composition containing the hibiscus extract of the present invention is added may take the form of a solution, an emulsion, a viscous mixture or the like.

That is, in one aspect, the cosmetic of the present invention is not particularly limited in its formulation, and examples thereof include an emulsion, cream, lotion, essence, pack, gel, powder, makeup base, foundation, lotion, ointment, patch, Formulations such as foam, cleansing cream, cleansing water, body lotion, body cream, body oil, body essence, shampoo, rinse, body cleanser, soap, hair dye, spray and the like.

In the cosmetic composition of each formulation, the components other than the above-mentioned Hibiscus extract may be mixed and selected without difficulty by those skilled in the art depending on the formulations of the other cosmetic preparations or the purpose of use.

In addition, in one aspect, the cosmetic of the present invention may comprise a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.

In one aspect, the cosmetic composition of the present invention may contain, in addition to the above essential ingredients, other ingredients usually added to cosmetics, if necessary.

Examples of the compounding ingredients that may be added include organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.

The components to be added in addition to these components are not limited thereto, and any of the above components can be compounded within a range that does not impair the objects and effects of the present invention.

In one aspect, the pharmaceutical composition comprising the hibiscus extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the production of pharmaceutical compositions.

As the formulation, the pharmaceutical composition containing the hibiscus extract may be administered orally, such as tablets, capsules, powders or syrups, or external preparations such as ointments, gels, creams, patches or sprays, And may be formulated and used in any form suitable for a clinical formulation.

In general, it is to be understood that the actual dosage of the active ingredient administered by the pharmaceutical composition should be determined in light of various relevant factors such as the severity of the symptoms, the route of administration selected, the age, sex, weight and health status of the subject. In general, the dosage of the active ingredient may be from 0.0001 mg / kg / day to 3000 mg / kg / day, for example from 10 mg / kg / day to 500 mg / kg / day.

In the health functional food composition as one aspect of the present invention, the health food is produced by using a raw material or a component (functional raw material) having a function useful for a nutrient or a human body which is likely to be deficient in a daily meal, Or to maintain or improve health through the activation of physiological functions. However, the present invention is not limited thereto. The health food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and circles, but is not limited thereto and may be manufactured and processed in any form according to the law.

Specifically, the health beverage composition has no particular limitation on the other ingredients other than the above-mentioned compounds as essential ingredients in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients such as ordinary beverages. Examples of natural carbohydrates are conventional sugars such as monosaccharide polysaccharides, cyclodextrins and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be used as flavorings other than those described above.

In general, it should be understood that the actual dosage of the active ingredient administered by the health functional food composition should be determined in light of various relevant factors such as the severity of the symptoms, the selected route of administration, the age, sex, weight and health status of the subject . In general, the dosage of the active ingredient may be from 0.0001 mg / kg / day to 1000 mg / kg / day, for example from 0.02 mg / kg / day to 6 mg / kg / day.

Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to examples. However, these examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited by the following examples.

[Example 1] Preparation of hibiscus oil extract

Hibiscus syriacus was cultivated in Gyeongsangbuk - do, and the one obtained from Moa - Cam was used. The obtained shells were extracted with an extraction solvent mixture of purified water and ethanol at a ratio of 3: 7, that is, 70% ethanol as an extraction solvent, and the alcohol was evaporated. After extracting at room temperature, primary filtration was performed to remove the solid material contained in the extract. Then, the extract was concentrated to remove ethanol, and then it was separated and purified. After centrifugation, secondary filtration and drying, the extracts were obtained.

[Example 2] Fine dust collection and extraction

The filter pack was used for about 24 hours by replacing the filter and denuder at around 10:00 am on each measurement day. The filter pack and the denuder were replaced by a low volume air sampler (Sensidyne, Gillian, Low Volume Air Sampler, FL, USA) Respectively. For 28 days, fine dust was collected daily from the windy area of Seoul (Gyeonggi-do, Korea), and the measurement time was measured by turning on the timer while turning on the vacuum pump and turning off the timer Time was recorded. The flow rate was measured with a flow meter (Model 4143, TSI Inc.) at the start of the measurement at a flow rate of 16.7 L / min, and the flow rate was measured again at the end of the measurement. The Teflon filter in the filter pack weighed before and after sampling. Before measuring the weight of the Teflon filter, the sample was weighed into a desiccator (NIKKO, Japan) with a relative humidity of 40% for 24 hours and then weighed twice on an electronic balance (DVG215CD, Ohaus) . After the sample was collected, the sample was weighed in a desiccator for 24 hours before measuring the weight, and then the weight was measured twice, and the mass concentration was calculated by comparing with the weight measured before the sampling. The extraction of fine dust was carried out by wetting the Teflon filter with 1 mL of ethanol, placing the filter with 14 mL of DW, closing the lid with the filter surface of the filter touching the water surface, and ultrasonically applying the filter with the ultrasonic cleaner for 30 minutes. In order to minimize the error caused by moisture in the filtration step, the water content of the filter was completely removed for 48 hours in a decicator, and then the weight of the filter was measured using a super-precision scale system (Mettler Toledo Company) Weighed and weighed before and after filter extraction.

[Example 3] Culture of keratinocyte (normal human) cell line

Human normal epidermal keratinocytes were purchased from Lonza, Inc. (Walkersville, Maryland, USA), subcultured and cultured in a CO 2 incubator at 37 ° C under 5% CO 2 Lt; / RTI > The cell culture was in accordance with Lonza's guidelines. (KGM-2 Bullet kit, CC-4152) (ingredient: BPE (bovine pituitary extract)), human epidermal growths (KBM- (Gentamycin Suflate + Amphofericin-B: GA), human epidermal growth factor (hEGF), insulin, Hydrocortisone, Transferrin, Epinephrine and gentamycin sulfate (KGM-2 Bullet Kit, CC-3107) was added to the reaction mixture.

[Example 4] (normal human) Treatment of fine dust and cytotoxicity measurement on keratinocyte cell line

MTT experiments were carried out using keratinocyte lines (normal human) by the method of Mossman et al. (J. Immunol. Methods, 65, 55-63, 1983) in order to confirm cytotoxicity through fine dusting.

Specifically, using a 24-well plate, and the cell culture conditions of Example 3 taken to prepare a dispersion of fine particles by dispersing the fine particles in the obtained diameter 2.5㎛ in purified water in the following Example 4 2.5 × 10 ⁵ Cells cultured under the conditions of the number of well cells were treated with the fine dust dispersion and cultured for 24 hours. Then, 5 mg / ml of MTT (3-4,5-dimethylthiazol-2,5-diphenyltetra zolium bromide) Lt; 0 > C for 3 hours. The medium was then removed and the formazan crystal formed was dissolved in 500 占 퐇 of DMSO. The lysate was transferred to a 96-well plate and aliquoted and the OD value measured at 540 nm absorbance. The measurement results are shown in Fig.

As shown in FIG. 1, the concentration (IC20) showing an 80% survival rate with respect to cytotoxicity by a dispersion in which fine particles of 2.5 micrometer or less were dispersed in the cell line was 12.5 g / Ml.

[Example 5] Confirmation of cellular genetic change of fine dust through next generation sequencing

For RNA-base sequence data processing and analysis, reference was made to the general analysis step developed by Trapnell et al. (2012). We confirmed the RNA-seq data quality using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and used FASTX (http://hannonlab.cshl.edu/fastx_toolkit/) , Thereby removing the base and the adder sequences with low accuracy. Afterwards, alignment was performed using Tophat (Trapnell et al., 2009) and human genome (hg19), and the amount of data for each sample was confirmed using EVER-seq renamed RSeQC (Wang et al., 2012 ). In addition, the level of expression of transcripts was quantified using Cufflinks, and transcription levels were compared between the fine dust dispersion treated and normal samples (Trapnell et al., 2010). A stringent cutoff of ≥2.0 fold-change was applied to the FDR adjusted p-value <0.05 to determine the gene that showed significant expression differences in the treatment of the dispersion of fine dust with a diameter of 2.5 μm. The measurement results are shown in the following [Table 2] and [Figure 2].

Increase gene Name Gene
Symbol Drainage variation NM_002963 S100A7 23.8

[Example 6] Real-time RT-PCR quantitation

Human microkeratin skin cells cultured in Example 3 in the amount of fine particles having a diameter of 2.5 占 퐉 extracted in Example 2 were treated in an amount of 12.5 占 퐇 in 1 ml of the cell culture medium and applied to the applied biosystems TaqMan® Primers) to determine the relative mRNA expression levels. The extract of Mugunghwa was the one prepared in Example 1.

Increase gene Name Gene
Symbol TaqMan® primer NM_002963 S100A7 Hs00161488_m1

After 24 hours, the culture solution was removed, and the cells were washed with 2 ml of phosphate buffered saline (PBS). Then, Trizol reagent (Invitrogen, Carlsbad , CA, USA). The separated RNA was further purified with an RNA kit (QIAGEN RNeasykt, QIAGEN, Valencia, Calif.) From Agilent Technologies, Inc., Agilent 2100 BioAnalyzer, Agilent Technologies, Santa Clara, ) Was used to confirm the quality of the RNA. CDNA was synthesized from the above RNA using a reverse transcription kit (Invitrogen, Carlsbad, Calif.) Of Invitrogen, and the cDNA was synthesized using the primers in the real time reverse transcription polymerase chain reaction (Q -RT-PCR: real-time reverse transcription polymerase chain reaction). The gene expression patterns of the cells were evaluated by real-time PCR using a TaqMan gene expression assay kit (Applied Biosystems, Foster City, Calif.) Of Applied Biosystems. Respectively. Both Q-RT-PCR and real-time PCR were performed according to the standard protocols distributed by Life Technologies. Specifically, the Q-RT-PCR was performed at 95 ° C for 20 seconds, followed by 95 ° C for 3 seconds and 60 ° C for 30 seconds For 40 cycles.

As shown in FIG. 2, there is a gene whose expression level increases in skin cells stimulated by fine dust, and it was confirmed that the expression amount of S100 calcium binding protein A7 (S100A7) gene was decreased by treatment with the extract of Mugunghwa extract .

Thus, it can be seen that the hibiscus extract effectively protects the skin cells from stimulation by the antimicrobial peptide, and inhibits or prevents the change in the expression level of the specific gene described above by the stimulation, so that the expression level of the normal level can be obtained have.

Hereinafter, formulation examples of the composition according to the present invention will be described. However, the cosmetic composition, the pharmaceutical composition and the health functional food composition can be applied to various formulations, and the present invention is not limited thereto .

 [Formulation Example 1] Tablets

The tablets were prepared by mixing 100 mg of the extract of Hibiscus rosea, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate according to the present invention, followed by tableting according to a conventional method for preparing tablets.

Compounding ingredient Content (mg) Mugunghwa extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2

[Formulation Example 2]

100 mg of Hibiscus L. extract according to the present invention, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate were mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.

Compounding ingredient Content (mg) Mugunghwa extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2

[Formulation Example 3]

50 mg of Hibiscus rosea extract, 250 mg of anhydrous crystalline glucose, and 550 mg of starch were mixed and granulated into granules using a fluidized bed granulator.

Compounding ingredient Content (mg) Mugunghwa extract 50 Anhydrous crystalline glucose 250 Starch 550

[Formulation Example 4] Soap

Compounding ingredient content(%) Mugunghwa extract 5.00 maintain Suitable amount Sodium hydroxide Suitable amount Sodium chloride Suitable amount Spices Suitable amount Purified water Balance

[Formulation Example 5] Lotion

Compounding ingredient content(%) Mugunghwa extract 5.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Water soluble collagen (1% aqueous solution) 1.00 Sodium citrate 0.10 Citric acid 0.05 Licorice extract 0.20 1,3-butylene glycol 3.00 Purified water Balance

[Formulation Example 6] Cream

Compounding ingredient content(%) Mugunghwa extract 3.00 Polyethylene glycol monostearate 2.00 Self emulsifying monostearic acid glycerin 5.00 Cetyl alcohol 4.00 Squalene 6.00 Tri-2-ethylhexanoic acid glyceryl 6.00 Sphingoglycolipids 1.00 1,3-butylene glycol 7.00 Purified water Balance

[Formulation Example 7] ointment

Compounding ingredient content(%) Mugunghwa extract 5.00 Polyvinyl alcohol 13.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Lauroylhydroxyproline 1.00 Water soluble collagen (1% aqueous solution) 2.00 1,3-butylene glycol 3.00 ethanol 5.00 Purified water Balance

 [Formulation Example 8] Preparation of serum

Compounding ingredient content(%) Mugunghwa extract 3.00 Hydroxyethylene cellulose (2% aqueous solution) 12.00 Xanthan gum (2% aqueous solution) 2.00 1,3-butylene glycol 6.00 Concentrated glycerin 4.00 Sodium hyaluronate (1% aqueous solution) 2.00 Purified water Balance

[Formulation Example 9] Health food

Compounding ingredient content Mugunghwa extract 2 mg Vitamin A acetate 70 μg Vitamin E 1.0 mg Vitamin B1 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 μg Vitamin C 10 mg Biotin 10 μg Nicotinic acid amide 1.7 mg Folic acid 50 μg Calcium pantothenate 0.5 mg Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium monophosphate 15 mg Dicalcium phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg

[Formulation Example 10] Health drinks

Compounding ingredient content Mugunghwa extract 50 mg Citric acid 1000 mg oligosaccharide 100 g Taurine 1g Purified water Balance

Claims (10)

A composition for inhibiting antimicrobial peptides, comprising an extract of Aspergillus oryzae as an active ingredient. The method according to claim 1,
Wherein said hibiscus extract is included in an amount of 0.000001 to 30% by weight based on the total weight of the composition. The method according to claim 1,
Wherein the extract is selected from the group consisting of water, C ₁ -C ₆ anhydrous or lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane . &Lt; / RTI &gt; The method according to claim 1,
Wherein said hibiscus extract is extracted from the bark of the cow. The method according to claim 1,
Wherein the antimicrobial peptide comprises S100A7 (NM_002963). 6. The method of claim 5,
Wherein the composition is applied to keratinocytes. The method according to claim 1,
Wherein said hibiscus extract is administered at a dose of 10 to 500 mg / kg / day. The method according to claim 1,
Wherein the composition is a cosmetic composition. The method according to claim 1,
Wherein the composition is a pharmaceutical composition. The method according to claim 1,
Wherein the composition is a health functional food composition.

Images